Obinnaya Emerole, MD
Cardiology · Macon, GANPI 1558314252
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,814 of the $8,062 with a category attached, or 84.5%. It is spread thinly across 38 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,820, 2.1 times the $1,324 reported in 2019.
Across 251 payments — averaging $32.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$2K
- Boston Scientific$685
- Pfizer$612
- AstraZeneca$585
- Abbott$387
- Merck$364
- plus $4K from 32 others
Across 6 payments — averaging $10,138 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$61K
What the payments were for
- Travel & lodging$1,22515%
- Food & beverage$6,81485%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 12 | $1,856 |
| Boston Scientific | 13 | $685 |
| Pfizer | 30 | $612 |
| AstraZeneca | 30 | $585 |
| Abbott | 11 | $387 |
| Merck | 21 | $364 |
| Novartis | 21 | $327 |
| Novo Nordisk | 6 | $304 |
| Shockwave Medical, Inc | 3 | $277 |
| GSK | 16 | $259 |
| Alnylam Pharmaceuticals Inc. | 7 | $234 |
| Scpharmaceuticals Inc. | 6 | $219 |
| Heartflow, Inc. | 2 | $217 |
| Medtronic | 2 | $209 |
| Amgen | 11 | $202 |
| Kestra Medical Technology Services, Inc. | 10 | $172 |
| Johnson & Johnson | 9 | $157 |
| Medicomp Inc | 4 | $123 |
| Abiomed | 4 | $115 |
| Smith+Nephew | 1 | $86 |
| Sanofi-aventis U.S. LLC | 4 | $79 |
| Bayer | 4 | $76 |
| E.r. Squibb & Sons, L.L.C. | 4 | $64 |
| Angiodynamics, Inc. | 1 | $58 |
| Daiichi Sankyo Inc. | 2 | $54 |
| Arbor Pharmaceuticals, Inc. | 4 | $52 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Vital Connect, Inc | 1 | $34 |
| Watermark Medical, Inc. | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Cvrx, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Cardiva Medical, Inc. | 1 | $20 |
| Biotronik Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Terumo Medical Corporation | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Gilead | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,062 in reported general payments places this provider in the 70th percentile of 24 cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 311 | $241,755 |
| OzempicSemaglutide | 227 | $241,706 |
| EntrestoSacubitril/Valsartan | 183 | $165,850 |
| FarxigaDapagliflozin Propanediol | 220 | $162,263 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 143 | $107,515 |
| MounjaroTirzepatide | 56 | $63,131 |
| JardianceEmpagliflozin | 57 | $42,615 |
| XareltoRivaroxaban | 51 | $39,702 |
| BrilintaTicagrelor | 30 | $21,604 |
| RybelsusSemaglutide | 15 | $18,644 |
| Repatha SyringeEvolocumab | 19 | $17,161 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $9,135 |
| Ranolazine ErRanolazine | 97 | $7,883 |
| Metoprolol Succinate | 518 | $4,121 |
| PradaxaDabigatran Etexilate Mesylate | 19 | $3,606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $304 | $260,350242 claims |
| PfizerEliquis | $612 | $241,755311 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere | $585 | $193,002264 claims |
| NovartisEntresto | $327 | $165,850183 claims |
| GSKTrelegy Ellipta | $259 | $107,515143 claims |
| Boehringer IngelheimJardiance, Pradaxa | $23 | $46,22176 claims |
| Johnson & JohnsonXarelto | $157 | $39,70251 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 24 cardiology providers in Georgia.
Other cardiology in Macon
- Chukwuemeka NwabueboMacon$877
- Rajinder ChhokarColumbus$17K
- Kalaivani SivakumarAtlanta$16K
- Zulfiquar BhattiColumbus$16K
- Vaibhav PatelColumbus$15K
- Samir MewarColumbus$15K
- Robert LemboSavannah$10K
- Mark WatkinsBrunswick$4K
- Annie HoAtlanta$2K
- John SmithAtlanta$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.